Antonin Schmitt

5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer

Katarzyna Morawska, Françoise Goirand, Laurine Marceau et al. · Oncotarget · 2018 · 69 citations · Full text

Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

Dejan Juric, Jordi Rodón, Ana M. González-Angulo et al. · Cancer Research · 2012 · 61 citations

Chemoprevention Strategy, Preliminary Safety, Bayesian Regression Model +16

A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients

Antonin Schmitt, Laurence Gladieff, Amélie Lansiaux et al. · Clinical Cancer Research · 2009 · 57 citations

Factors for Hematopoietic Toxicity of Carboplatin: Refining the Targeting of Carboplatin Systemic Exposure

Antonin Schmitt, Laurence Gladieff, Céline M. Laffont et al. · Journal of Clinical Oncology · 2010 · 55 citations · Full text

A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma

Julia Jolibois, Antonin Schmitt, Bernard Royer · Journal of Chromatography B · 2019 · 49 citations · Full text

Bioanalysis, Mass Spectrometry, Pharmacology +10